Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data

por Armstrong, April W., Koning, J. Will, Rowse, Simon, Tan, Huaming, Mamolo, Carla, Kaur, Mandeep
Publicado en Dermatol Ther (Heidelb) (2016)

A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies

por Callis Duffin, Kristina, Bushmakin, Andrew G., Cappelleri, Joseph C., Mallbris, Lotus, Mamolo, Carla
Publicado en BMC Dermatol (2019)

Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes

por Panés, Julián, Su, Chinyu, Bushmakin, Andrew G, Cappelleri, Joseph C, Mamolo, Carla, Healey, Paul
Publicado en BMC Gastroenterol (2015)

Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom

por Castejón, Nacho, Cappelleri, Joseph C., Cuervo, Jesús, Lang, Kathryn, Mehta, Priyanka, Mokgokong, Ruth, Mamolo, Carla
Publicado en Health Qual Life Outcomes (2018)

Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews

por Lee, Lauren J, Kwon, Christina S, Forsythe, Anna, Mamolo, Carla M, Masters, Elizabeth T, Jacobs, Ira A
Publicado en Clinicoecon Outcomes Res (2020)

Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia

por Mamolo, Carla, Welch, Verna, Walter, Roland B., Cappelleri, Joseph C., Brockbank, James, Cawson, Matthew, Knight, Chris, Wilson, Michele
Publicado en Pharmacoeconomics (2020)

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia

por Brümmendorf, Tim H., Gambacorti-Passerini, Carlo, Bushmakin, Andrew G., Cappelleri, Joseph C., Viqueira, Andrea, Reisman, Arlene, Isfort, Susanne, Mamolo, Carla
Publicado en Ann Hematol (2020)

Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial

por Papp, Kim A., Bissonnette, Robert, Gooderham, Melinda, Feldman, Steven R., Iversen, Lars, Soung, Jennifer, Draelos, Zoe, Mamolo, Carla, Purohit, Vivek, Wang, Cunshan, Ports, William C.
Publicado en BMC Dermatol (2016)

Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or int...

por Kantarjian, Hagop M., Mamolo, Carla M., Gambacorti‐Passerini, Carlo, Cortes, Jorge E., Brümmendorf, Tim H., Su, Yun, Reisman, Arlene L., Shapiro, Mark, Lipton, Jeff H.
Publicado en Cancer (2017)

Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses

por Baker, Erica L., Coleman, Craig I., Reinhart, Kurt M., Phung, Olivia J., Kugelman, Lisa, Chen, Wendy, White, C. Michael, Mamolo, Carla M., Cappelleri, Joseph C., Baker, William L.
Publicado 2012